ATHE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Alterity Therapeutics Ltd (ATHE) is not a strong buy at this time for a beginner investor with a long-term strategy. While the stock has shown a slight positive price change recently and has speculative buy coverage from analysts, the lack of significant trading trends, financial performance data, and clear positive catalysts makes it prudent to hold off on investing until more concrete data or signals emerge.
The MACD is positively expanding, indicating mild bullish momentum. The RSI is neutral at 69.456, and moving averages are converging, suggesting no strong trend. The stock is trading near its resistance level of 3.568, with support at 3.301. Overall, the technical indicators do not strongly favor a buy at this time.
Speculative buy rating from Canaccord with a price target of $A1.6c. The company is addressing an unmet need in neurodegenerative diseases, which could be a long-term positive catalyst.
No significant hedge fund or insider trading trends. Lack of recent news or event-driven catalysts. No recent congress trading data. Limited financial and valuation data available.
No financial performance data available for analysis.
Canaccord initiated coverage with a speculative buy rating and a price target of $A1.6c, citing the company's focus on addressing unmet needs in neurodegenerative diseases.
